Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Cartesian Therapeutics, Inc. Common Stock

RNAC

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Last trade $6.09
Day change +$0.01 (+0.16%)
Day range $5.92 – $6.43
Volume 112,587
Market cap $185M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$185.46M
Price / earnings
—
Price / book
-1.42×
Price / sales
180.93×
EV / sales
109.95×
EV / EBITDA
-1.13×

Profitability

Earnings per share
-$4.25
Return on assets
-44.01%
Return on equity
99.27%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.38×
Current ratio
8.38×
Quick ratio
8.38×
Cash ratio
7.83×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$89.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RNAC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$78K$947K$452K$298K$1.1M—
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$78K$947K$452K$298K$1.1M—
Selling, general and administrative$9.38M$8.72M$7.11M$8.2M$7.72M$7.24M$8.32M—
Research and development$15.62M$20.43M$19.46M$14.69M$13.8M$14.87M$14.67M—
Total operating expenses$25M$29.16M$26.58M$79.59M$21.52M$22.11M$22.99M—
Operating income-$25M-$29.16M-$26.5M-$78.64M-$21.07M-$21.81M-$21.89M—
Interest expense-$1.99M-$852K$0$0$0$0$0—
Income before taxes-$11.47M$15.77M-$39.18M-$101.77M-$35.9M$15.89M-$17.71M—
Income taxes$0$0$0-$9.19M$0$0$0—
Net income-$11.47M$15.77M-$39.18M-$92.58M-$35.9M$15.89M-$17.71M—
Net income attributable to common shareholders-$11.47M$13.72M-$39.18M-$92.58M-$35.9M$13.26M-$17.71M—
EBITDA-$24.22M-$28.38M-$25.88M-$21.33M-$20.46M-$21.22M-$20.73M$486K
Basic earnings per share-$0.38$0.47-$1.46-$3.56-$1.38$0.51-$0.68—
Diluted earnings per share-$0.38$0.46-$1.46-$3.62-$1.38$0.50-$0.68—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.

GlobeNewswire Inc.

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

GlobeNewswire Inc.

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending cash runway into 2028. The company expects Phase 3 AURORA trial topline data for Descartes-08 in myasthenia gravis in Q1 2027, with BLA filing planned for mid-2027. Additional clinical data from Phase 2 TRITON (myositis) and Phase 1/2 HELIOS (juvenile dermatomyositis) trials are expected in H1 2027.

GlobeNewswire Inc.

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 5, 20241-for-30reverse split
Dec 1, 20232-for-1stock dividend